Dentsply Sirona Inc. is a diversified manufacturer of professional dental products and technologies, as well as healthcare consumables for urology and enterology. The company operates through four reportable segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. Its product portfolio includes dental imaging equipment, CAD/CAM systems, intraoral scanners, dental implants, clear aligners, endodontic and restorative materials, and continence care devices such as catheters and irrigation systems. Dentsply Sirona serves dental practitioners, specialists, and laboratories globally, with significant presence in the United States, Europe, Asia-Pacific, and the Americas. The company offers the DS Core cloud-based platform for digital services and integrates hardware, software, and equipment to support digital workflows. Founded in 1899 as The Dentists’ Supply Company and formed through a 2016 merger with Sirona Dental Systems, the company markets its products under established brands including CEREC, SureSmile, Astra Tech, and LoFric.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage dentsplysirona.com
Sector Healthcare IR page investor.dentsplysirona.com
Tags
dental equipment, dental implants, clear aligners, cad/cam, endodontics, restorative dentistry, continence care, urology, enterology, cloud-based software, intraoral scanners, digital dentistry, CEREC, SureSmile, DS Core, Astra Tech, LoFric, IRM, Cavitron, ProTaper Universal, SureFil SDR, GuttaCore, WaveOne, e3, RDH Freedom, Celtra Duo, LoFric Origo, Cavitron Touch, Cercon HT, XSmart iQ, ceram.x Universal, Trubyte, Gendex, Tulsa Dental Products, Maillefer Instruments, CeraMed Dental, Ceramco, GAC International, Zhermack, Wellspect Healthcare, Byte
Press page —

Metrics

Valuation  
Market cap $ 1.756B
Market cap (USD) $ 1.756B
P/E -14.29
PEG —
P/BV 1.30
P/S 0.49
P/OCF 6.46
P/FCF 16.89
Dividend yield 7.2%
Turnover / mcap —
Returns  
ROE -36.5%
ROI -16.7%
ROIC -8.8%
Profit margin -16.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 162.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score -36.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 3.68B 3.793B 3.965B 3.922B 4.251B 3.342B 4.029B 3.986B 3.993B 0 0 2.923B 2.951B 2.928B 2.538B 2.221B 2.16B 2.194B 2.01B 1.81B 1.715B 1.694B 1.571B 1.514B 1.129B 889.796M
Net profit -598M -910M -132M -950M 421M -83M 262.9M -1.011B -1.55B 429.9M 251.2M 322.854M 313.192M 314.213M 244.52M 265.708M 274.258M 283.869M 259.654M 223.718M 45.413M 253.165M 174.183M 147.952M 121.496M 101.016M
Free cash flow 104M 281M 228M 368M 515M 548M 509.9M 317.3M 457.6M 438.4M 425.4M 460.823M 317.501M 277.613M 322.283M 318.088M 306.008M 259.541M 323.534M 221.239M 187.476M 250.002M 181.409M 115.529M 161.731M 117.197M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 11.43 18.98 35.59 31.84 55.79 52.36 56.59 37.21 65.83 57.73 60.56 55.45 48.5 40.5 39.53 15.58 34.98 29.87 44.09 32.17 — — — — — —
Price performance 12m -0.4 -0.47 0.12 -0.43 0.07 -0.07 0.52 -0.43 0.14 -0.05 0.09 0.14 0.2 0.02 1.54 -0.55 0.17 -0.32 0.37 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 636M 746M 702M 782M 673M 747M 632M 695M 556M 688M
↳ YoY growth +59.0% +17.3% -5.9% +11.4% -13.9% +11.0% -15.4% +10.0% -20.0% +23.7%
↳ 5y CAGR +8.3% +11.0% +8.2% +12.9% +11.0% +3.3% -3.3% -0.2% -6.6% +0.4%
Borrowings, current (USD) 11M 9.2M 10.6M 200,000 296M 1M 1M 77M 128M 228M
Borrowings, non-current (USD) 1.51B 1.61B 1.56B 1.43B 1.98B 1.91B 1.83B 1.8B 1.59B 2.02B
Lease liabilities (USD) — — — 165M 179M 197M 205M 182M 137M 140M
Cash and deposits (USD) 384M 321M 310M 405M 438M 339M 365M 334M 272M 326M
Intangible assets (USD) 2.96B 2.8B 2.42B 2.18B 2.5B 2.32B 1.9B 1.71B 1.21B 974M
Right-of-use assets (USD) — — — 159M 176M 193M 200M 178M 136M 139M
Net debt (borrowings + leases - cash) (USD) 1.14B 1.3B 1.27B 1.19B 2.02B 1.77B 1.67B 1.72B 1.58B 2.06B
Cash flow detail
Operating cash flow (USD) 563M 602M 500M 633M 635M 657M 517M 377M 461M 235M
Purchases of property, plant and equipment (USD) -125M -144M -183M -123M -87M -142M -149M -149M -180M -131M
Purchases of intangible assets (USD) -1.1M -6.7M -5.5M 0.00 0.00 — — — — —
Change in receivables (cash effect) (USD) -75.1M -63.4M 23.5M -91.4M 126M -109M 85M -58M 104M -91M
Change in inventories (cash effect) (USD) 65.4M -62.9M -19.9M 13.7M 124M -63M -141M 6M 17M -17M
Change in payables (cash effect) (USD) 7.2M 44.2M 7.1M 26.1M -23M -46M 30M 14M -30M 11M
Dividends paid (cash effect) (USD) -64.6M -78.3M -78.6M -80.9M -88M -92M -104M -116M -126M -128M
Share buybacks (cash effect) (USD) -814M -401M -250M -260M -140M -200M -150M -300M -250M 0.00
Interest paid (cash effect) (USD) -36.7M -37M -35.1M -30.2M -45M -64M -70M -97M -91M -66M
Income taxes paid (cash effect) (USD) -112M -123M -105M -112M -82M -148M -122M -177M -74M -71M
Share-based compensation (USD) 41.3M 48M 21M 66.2M 47M 48M 59M 46M 39M 33M
Operating cash flow before change in receivables (USD) 639M 665M 476M 724M 509M 766M 432M 435M 357M 326M
Free cash flow (OCF - PPE - intangibles) (USD) 437M 451M 312M 510M 548M 515M 368M 228M 281M 104M
Income detail
Research and development expense (USD) 129M 152M 161M 131M 115M 171M 174M 184M 165M 150M
↳ 5y CAGR +14.0% +12.2% +13.5% +10.2% +9.0% +5.9% +2.8% +2.8% +4.7% +5.5%
Total comprehensive income (USD) 319M -1.14B -1.2B 143M 54M 291M -986M -140M -1B -507M
Comprehensive income to owners (USD) 318M -1.14B -1.2B 142M 53M 293M -986M -140M -1B -507M
Reported Mar 1, 2017 Mar 15, 2018 Mar 8, 2019 Mar 2, 2020 Mar 1, 2021 Mar 1, 2022 Mar 1, 2023 Feb 29, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Dentsply Sirona Reports Third Quarter 2026 Results Bull 4 Bear 3 Results

November 5, 2026

PDF Version

News Summary

  • Q3 2026 net sales of**$836 million**

  • Q3 2026 GAAP gross margin of52.9%, GAAP diluted loss per share of**($0.01)**

  • Q3 2026 adjusted gross margin of54.5%,adjusted EBITDA marginof17.3%, adjusted EPS of**$0.29**

  • **Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth; completed the U.S. Surity™portfolio with the launch of the Surity™**Urinary Management System

  • Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30

CHARLOTTE, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2026.

"We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network. Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth."

Q3 2026 Summary Results (Reported)

Gross profit and adjusted EBITDA include a $39 million benefit from the refinement of our estimate to eliminate unrealized profit in inventory. The adjustment reduces the reported net loss and increases adjusted net income by approximately $30 million. This amount represents the cumulative impact of the revised estimate and equivalent impacts are not expected in future.

| (in millions, except per share amount and percentages) | | Q3 26 | | Q3 25 | | YoY |

| | | | | | | |

| Net Sales | | $836 | | $904 | | (7.6%) |

| Gross Profit | | $443 | | $441 | | 0.3% |

| Gross Margin | | 52.9% | | 48.8% | | |

| Net Loss Attributable to Dentsply Sirona | | ($2) | | ($427) | | NM |

| Diluted Loss Per Share1 | | ($0.01) | | ($2.14) | | NM |

Q3 2026 Summary Results (Non-GAAP)

| (in millions, except per share amount and percentages) | | Q3 26 | | Q3 25 | | YoY |

| | | | | | | |

| Constant Currency Sales | | | | | | (7.0%) |

| Adjusted EBITDA | | $146 | | $167 | | (13.3%) |

| Adjusted EBITDA Margin | | 17.3% | | 18.4% | | |

| Adjusted EPS | | $0.29 | | $0.42 | | (29.4%) |

NM - not meaningful Percentages are based on actual values and may not reconcile due to rounding. [1] Weighted-average shares outstanding used to calculate diluted loss per share for the third quarter of 2026 excludes potential dilutive common shares.

Q3 2026 Results by Region and Segment (Reported and Non-GAAP) (in millions, except percentages)

| | | | | | Percentage Change |

| Net Sales by Segment | | | Three Months Ended September 30, 2026 vs. 2025 |

| | | | | | | | | Americas | | EMEA | | APAC |

| | | | | | | | | | | | | | | | |

| | 2026 | | 2025 | | As Reported1 | Constant Currency1 | | As Reported | Constant Currency | | As Reported | Constant Currency | | As Reported | Constant Currency |

| | | | | | | | | | | | | | | | |

| Connected Technology Solutions | $ | 230 | | $ | 259 | | (11.0)% | (10.1)% | | (21.6)% | (21.9)% | | (5.5)% | (4.2)% | | (4.7)% | (2.5)% |

| Essential Dental Solutions | | 343 | | | 357 | | (4.0)% | (3.6)% | | (0.6)% | (0.8)% | | (7.7)% | (6.5)% | | (4.4)% | (4.2)% |

| Orthodontic and Implant Solutions | | 171 | | | 205 | | (16.6)% | (16.2)% | | (22.9)% | (23.1)% | | (13.5)% | (12.3)% | | (7.3)% | (7.2)% |

| Wellspect Healthcare | | 92 | | | 83 | | 10.1% | 11.0% | | 77.3% | 78.6% | | 1.2% | 2.0% | | (1.0)% | 4.1% |

| Total | $ | 836 | | $ | 904 | | (7.6)% | (7.0)% | | (9.4)% | (9.6)% | | (6.7)% | (5.6)% | | (5.2)% | (4.3)% |

| (1) Constant currency sales are a Non-GAAP measure in which the reported net sales are adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales. |

Cash Flow and Liquidity

Operating cash flow in the third quarter of 2026 was $32 million, compared to $79 million in the third quarter of 2025, primarily driven by unfavorable working capital. Free cash flow, a Non-GAAP measure, in the third quarter of 2026 was $0 million compared to $40 million in the third quarter of 2025. In the third quarter of 2026, the Company repurchased 1.2 million shares of its common stock for a total of approximately $13 million, resulting in a total of $25 million returned to stockholders through share repurchases in the first nine months of 2026. The Company had $195 million of cash and cash equivalents as of September 30, 2026.

2026 Outlook

The Company is updating its 2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit from tariff refunds.

Without unreasonable effort, we are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.

Conference Call/Webcast Information Dentsply Sirona's management team will host an investor conference call and live webcast on November 5, 2026 at 4:30 p.m. ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at http://register-conf.media-server.com/register/BI087bbe14635a47a484497a4e4376efc9. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

October 20, 2026

PDF Version

CHARLOTTE, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 5, 2026, at 4:30 p.m. EST to review its third quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company’s website at https://investor.dentsplysirona.com prior to the call.

Conference Call / Webcast Information

The live webcast link and call information will be available on the Investors section of the Company’s website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register here. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

On October 8, 2026, DENTSPLY SIRONA Inc. (the “Company”) obtained the consent of the requisite lenders under its revolving credit facility, dated May 12, 2023, with JPMorgan Chase Bank, N.A., as administrative agent, to, among other things, amend certain provisions by entering into the Third Amendment to Credit Agreement, dated as of September 30, 2026 (the “Third Amendment to Credit Agreement”).

On October 8, 2026, the Company entered into the following agreements (collectively, the “Note Purchase Agreement Amendments”):

a.Note Purchase Agreement Amendment No. 5, dated as of September 30, 2026, by and among the Company and the noteholders party thereto with respect to the Note Purchase Agreement, dated as of December 11, 2015, by and among the Company and the other parties thereto; b.Note Purchase and Guarantee Agreement Amendment No. 5, dated as of September 30, 2026, by and among the Company, DENTSPLY DENTAL B.V.

Prompts

DENTSPLY SIRONA Inc. (ticker XRAY), listed in United States.

Company History

Date Change Detail
Feb 29, 2016 Renamed DENTSPLY INTERNATIONAL INC /DE/ → DENTSPLY SIRONA INC.

ETFs Holding DENTSPLY SIRONA Inc.

ETF Weight in ETF Shares Market value As of
BSMC 2.37% 371,967 $ 3.947M Jun 30, 2026
DWSH short -0.97% -6,972 $ -59.959K Nov 17, 2026
CCFE 0.95% 35,786 $ 310K Nov 18, 2026
SQLV 0.36% 9,811 $ 104.095K Jun 30, 2026
AIVL 0.21% 81,204 $ 861.574K Jun 30, 2026
FLCV 0.15% 19,001 $ 212.241K Aug 31, 2026
BSVO 0.15% 415,020 $ 3.57M Nov 18, 2026
VFVA 0.14% 120,905 $ 1.351M Aug 31, 2026
CDX short -0.14% -39,497.6106 $ -339.679K Nov 17, 2026
MSSM 0.12% 78,983 $ 882.24K Aug 31, 2026
AVSC 0.11% 408,639 $ 3.655M Nov 16, 2026
FESM 0.10% 553,580 $ 5.873M Jun 30, 2026
RESM 0.10% 341 $ 3,618.01 Jun 30, 2026
VFQY 0.06% 29,517 $ 329.705K Aug 31, 2026
VFMF 0.06% 55,889 $ 624.28K Aug 31, 2026
DFAS 0.03% 1,172,249 $ 10.832M Nov 12, 2026
MKTN 0.03% 3,202 $ 33.973K Jun 30, 2026
FTLS short -0.03% -86,257 $ 0.00 Nov 16, 2026
SMDX 0.03% 4,124 $ 36.889K Nov 17, 2026
DFAT 0.02% 545,065 $ 5.036M Nov 12, 2026
DFSV 0.02% 463,684 $ 4.284M Nov 12, 2026
DXUV 0.01% 98,628 $ 911.323K Nov 12, 2026
DFSU 0.01% 28,160 $ 260.198K Nov 12, 2026
AVSU 0.01% 3,214 $ 28.749K Nov 16, 2026
SFGV 0.01% 17,476 $ 150K Nov 18, 2026
DFAC 0.01% 730,423 $ 6.749M Nov 12, 2026
NPFE 0.01% 3,297 $ 44.081K Jul 31, 2026
DCOR 0.01% 243,715 $ 2.252M Nov 12, 2026
DFAU 0.00% 48,502 $ 448.158K Nov 12, 2026
MSLC 0.00% 7,927 $ 88.545K Aug 31, 2026
DFUS 0.00% 47,753 $ 441.238K Nov 12, 2026
AVUS 0.00% 59,630 $ 533.39K Nov 16, 2026
NTRL short 0.00% -6,636 $ 0.00 Nov 16, 2026